|Awarded On||November 19, 2014|
|Title||NKT Cell Platform for Cancer Immunotherapy|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Leonid S Metelitsa|
|Cancer Sites||All Sites|
The goal of this project is to develop a new class of cancer immunotherapy that exploits natural and engineered properties of Natural Killer T cells (NKTs) to target tumor-supportive stroma. Increasing numbers of clinical trials using adoptive T cell therapies are showing anti-tumor activity against a broad range of malignancies. However, tumor growth creates a highly immunosuppressive stroma which impairs T-cell homing to the tumor site or their anti-tumor function. This represents a major and as yet unsolved critical challenge to the development of effective adoptive immunotherapy of cancer.
The proposed project will develop banked or “off-the-shelf” NKTs engineered to express the cytokine...